A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the effect of alvelestat (an oral neutrophil
elastase inhibitor) on blood and sputum biomarkers in patients with PiZZ, null or rare
variant phenotype/genotype alpha-1 anti-trypsin deficient lung disease. Change in a number of
different blood and sputum biomarkers related to lung damage, inflammation and elastase
activity will be measured over a 12 week period. The effect on lung function and respiratory
symptoms will also be measured.